Use of DNA methyltransferase inhibitor and poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) in the treatment of PARPi-resistant, high-grade serous ovarian cancer

被引：0
作者：
Shafa, Anousheh [1 ]
Hou, Xiaonan [1 ]
Wang, Liewei [1 ]
Weroha, S. John [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
GYNECOLOGIC ONCOLOGY | 2024年 / 190卷
关键词：
D O I：
10.1016/j.ygyno.2024.07.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1275
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [21] Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Overview
    dos Reis, Rodolfo Borges
    Aguilar-Ponce, Jose L.
    Cayol, Federico
    Jansen, Angela M.
    Manneh, K. Ray
    Merino, Tomas R.
    Sanku, Gayatri
    Vaca, Laura B.
    Velho, Pedro Isaacsson
    Korbenfeld, Ernesto P.
    CANCER CONTROL, 2024, 31
  • [22] A Biomarker Study of Poly(ADP-ribose) Polymerase Inhibitor (PARPi) ABT-888 Activity On Ex Vivo Tissue From Ovarian Cancer Patients
    Weberpals, J.
    Ma, X.
    Dimitroulakos, J.
    Djordjevic, B.
    Lapointe-Milot, K.
    Al Mutairi, N.
    Pelletier, L.
    Oza, A.
    Squire, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 146 - 146
  • [23] Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC).
    Ang, J.
    Yap, T. A.
    Fong, P.
    Carden, C. P.
    Tan, D. S.
    Hanwell, J.
    Carmichael, J.
    De Bono, J. S.
    Gore, M. E.
    Kaye, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model
    Perez Fidalgo, J. A.
    Martinez Pretel, J. J.
    Heredia, V.
    Romeo Marin, M.
    Mendiola, M.
    Hochstadt, J.
    Bernat, A.
    Sanchez-Serrano, P.
    Redondo Sanchez, A.
    Gil Martin, M.
    Guerra Ojeda, S.
    Teruel, I.
    Burgues, O.
    Cervantes, A.
    Pineda Merlo, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S813 - S814
  • [25] The use of novel PP2A activators in combination with PARP inhibitor for the treatment of high-grade serous ovarian cancer
    Armstrong, A. J.
    Joseph, P.
    Nagaraj, A. B.
    Nagel, C. I.
    Nakayama, J.
    Waggoner, S. E.
    Zanotti, K. M.
    DiFeo, A.
    Narla, G.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 73 - 73
  • [26] Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in the Treatment of Advanced Ovarian Cancer: A Narrative Review
    Dewani, Deepika
    Jaiswal, Arpita
    Karwade, Pravin
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (09)
  • [27] Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
    Matulonis, U. A.
    Wulf, G. M.
    Barry, W. T.
    Birrer, M.
    Westin, S. N.
    Farooq, S.
    Bell-McGuinn, K. M.
    Obermayer, E.
    Whalen, C.
    Spagnoletti, T.
    Luo, W.
    Liu, H.
    Hok, R. C.
    Aghajanian, C.
    Solit, D. B.
    Mills, G. B.
    Taylor, B. S.
    Won, H.
    Berger, M. F.
    Palakurthi, S.
    Liu, J.
    Cantley, L. C.
    Winer, E.
    ANNALS OF ONCOLOGY, 2017, 28 (03) : 512 - 518
  • [28] What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?
    Rafii, Saeed
    Gourley, Charlie
    Ang, Joo Ern
    Kumar, Rajiv
    Geuna, Elena
    Rye, Tzyvia
    Ashcroft, Linda
    Powell, Bethan
    Shapira-Frommer, Ronnie
    Friedlander, Michael
    Chen, Lee-may
    Matulonis, Ursula
    Kaufman, Bella
    De Greve, Jacques
    Oza, Amit M.
    Banerjee, Susana N.
    Gore, Martin Eric
    Molife, L. Rhoda
    Kaye, Stanley B.
    Yap, Timothy Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] INTEGRATED EFFICACY AND SAFETY ANALYSIS OF THE POLY(ADP-RIBOSE) POLYMERASE INHIBITOR RUCAPARIB IN PATIENTS WITH HIGH-GRADE OVARIAN CARCINOMA
    Jairam-Thodla, Arati
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [30] Who is first in line? Trends in use of poly (ADP-ribose) polymerase inhibitors (PARPi) among commercially insured women with ovarian cancer
    Dottino, Joseph
    Argetsinger, Stephanie
    Costa, Rebecca
    Esselen, Katharine
    Ross-Degnan, Dennis
    Wagner, Anita
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S221 - S221
12345